Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Score, Valuation & Financial Research

Cadrenal Therapeutics, Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CVKD

Cadrenal Therapeutics, Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 1.08. These figures are a research snapshot, not a buy or sell recommendation.

What Cadrenal Therapeutics, Inc. Common Stock does

Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Cadrenal Therapeutics is a late-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the development of specialized cardiovascular therapeutics, specifically tecarfarin, and the acquisition of clinical-stage assets to build a pipeline for future commercialization.

Products and services

  • The company's primary product candidate is tecarfarin, an oral vitamin K antagonist designed to address unmet needs in anticoagulation therapy, particularly for patients with conditions like end-stage renal disease.

Customer types

Patients with end-stage renal disease and other anticoagulation needs.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on unnamed third-party contract research organizations to conduct and manage its clinical trials. Source

Business relationships and partnerships

  • Veralox Therapeutics Inc. — Cadrenal entered into an Asset Purchase Agreement with Veralox Therapeutics to acquire all or substantially all of its right, title, and interest in assets, including clinical programs, effective December 10, 2025. Source

Business strengths to evaluate

  • Focused development of tecarfarin for specific patient populations with unmet needs Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses Source
  • Dependence on the success of a single product candidate, tecarfarin Source
  • Reliance on third-party contract research organizations and manufacturers Source

Sources: Company research source · Veralox Therapeutics Inc.

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CVKD financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.08
Market capitalization:
3.85M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -11.54M
Free cash flow:
USD -12.61M
Cash:
USD 2.39M
Total debt:
USD 0.00
EPS:
USD -4.90

What stands out

  • Free cash flow is USD -12.61M, negative for the stored period.
  • The balance sheet shows USD 2.39M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 2.39M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CVKD

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CVKD fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CVKD likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CVKD to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CVKD's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research CVKD

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.